SCHEMBL16933575

SCHEMBL16933575

CC(C)(NC(=O)OC1CCN2CCC1CC2)c1cccc(Oc2cccc(C(=O)N3CCOCC3)c2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 1/20 0.48
▸ RAB9A P51151 2/20 0.46
▸ NR1H2 P55055 2/20 0.41
▸ NR1H3 Q13133 2/20 0.41
▸ ALDH1A1 P00352 3/20 0.41
▸ TSHR P16473 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ F10 P00742 1/20 0.41
▸ MEN1 O00255 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ EPHX2 P34913 1/20 0.39
▸ NSD2 O96028 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ PARP10 Q53GL7 1/20 0.39
▸ MAPT P10636 1/20 0.38
▸ CRHBP P24387 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ CRHR2 Q13324 1/20 0.38
▸ P2RX4 Q99571 1/20 0.38
▸ NTMT1 Q9BV86 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29387446 1.00 L3MBTL1 (0.48) L3MBTL1RAB9ANR1H2NR1H3ALDH1A1
SCHEMBL15577911 0.94 L3MBTL1 (0.47) L3MBTL1RAB9AALDH1A1NTMT1
SCHEMBL15578271 0.85 ALDH1A1 (0.42) ALDH1A1NSD2LMNANTMT1
SCHEMBL16933485 0.85 ALDH1A1 (0.45) ALDH1A1SMN1; SMN2KMT2AEPHX2LMNA
SCHEMBL29384728 0.85 ALDH1A1 (0.42) ALDH1A1NSD2LMNANTMT1
SCHEMBL16933663 0.84 ALDH1A1 (0.41) ALDH1A1NSD2LMNAMAPTNTMT1
SCHEMBL29387286 0.84 ALDH1A1 (0.41) ALDH1A1NSD2LMNAMAPTNTMT1
SCHEMBL16933468 0.81 NTMT1 (0.44) ALDH1A1EPHX2LMNANTMT1
SCHEMBL16933469 0.81 L3MBTL1 (0.58) L3MBTL1RAB9ANR1H2NR1H3ALDH1A1
SCHEMBL15578307 0.78 RAB9A (0.46) L3MBTL1RAB9ANR1H2NR1H3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250026749-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GENZYME CORPORATION (US) 2025-01-23 — — US disclosed
US-12060349-B2 Glucosylceramide synthase inhibitors GENZYME CORPORATION (US) 2024-08-13 — — US disclosed
EP-4098654-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS Genzyme Corporation (US) 2022-12-07 — — EP disclosed
US-20220073508-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GENZYME CORPORATION (US) 2022-03-10 — — US disclosed
EP-2895484-B1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GENZYME CORP (US) 2022-02-23 — — EP disclosed
US-11008316-B2 Glucosylceramide synthase inhibitors GENZYME CORPORATION (US) 2021-05-18 — — US disclosed
US-20180065957-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GENZYME CORPORATION (US) 2018-03-08 — — US disclosed
US-20150210681-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GENZYME CORPORATION (US) 2015-07-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150210681-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GBA1, GBA2, GAA L3MBTL1 1688/4885RAB9A 699/4885NR1H2 2110/4885
US-20180065957-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GBA1, GBA2, GAA L3MBTL1 1688/4885RAB9A 699/4885NR1H2 2110/4885
US-11008316-B2 Glucosylceramide synthase inhibitors GBA1, GBA2, GAA L3MBTL1 2336/4885RAB9A 641/4885NR1H2 1400/4885
US-12060349-B2 Glucosylceramide synthase inhibitors GBA1, GBA2, GALC L3MBTL1 3424/4885RAB9A 490/4885NR1H2 2720/4885
US-20250026749-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GBA1, GBA2, GAA L3MBTL1 1688/4885RAB9A 699/4885NR1H2 2110/4885
US-20220073508-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GBA1, GBA2, GAA L3MBTL1 1688/4885RAB9A 699/4885NR1H2 2110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback